CD47 Antibody (B6H12): sc-12730

CD47 Antibody (B6H12) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD47 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD47 (B6H12) antibody is available in both non-conjugated and various conjugated forms, including agarose, phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD47 is an integral membrane protein that plays a crucial role in regulating cation fluxes across cell membranes, particularly influencing the increase in intracellular calcium concentration during cell adhesion to the extracellular matrix. This function is vital for various cellular processes, including migration, proliferation, and survival, as CD47 helps cells respond appropriately to their environment. Additionally, CD47 serves as a receptor for the C-terminal cell-binding domain of thrombospondin, which is important for cell signaling and communication. Notably, CD47 is absent from Rh-null erythrocytes, yet CD47 significantly contributes to cell adhesion in non-erythroid cells and may prevent the premature elimination of erythrocytes from circulation. Furthermore, CD47 is expressed on a variety of cell types, including hemopoietic cells, epithelial cells, endothelial cells, and fibroblasts, with particularly strong expression in brain and mesenchymal cells, highlighting CD47′s importance in both normal physiology and potential pathological conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD47 Antibody (B6H12) References:

1. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.  |  Boerman, O., et al. 1989. Anticancer Res. 9: 551-8. PMID: 2764501
2. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.  |  Veillette, A. and Chen, J. 2018. Trends Immunol. 39: 173-184. PMID: 29336991
3. The CD47-SIRPα Immune Checkpoint.  |  Logtenberg, MEW., et al. 2020. Immunity. 52: 742-752. PMID: 32433947
4. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion.  |  Jiang, N., et al. 2022. Nat Commun. 13: 1511. PMID: 35314680
5. CD47/SIRPα axis: bridging innate and adaptive immunity.  |  van Duijn, A., et al. 2022. J Immunother Cancer. 10: PMID: 35831032
6. Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences.  |  Slobbe, R., et al. 1994. Clin Exp Immunol. 98: 95-103. PMID: 7523009
7. Changes in expression of differentiation markers between normal ovarian cells and derived tumors.  |  Van Niekerk, CC., et al. 1993. Am J Pathol. 142: 157-77. PMID: 7678716
8. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3.  |  Mawby, WJ., et al. 1994. Biochem J. 304 (Pt 2): 525-30. PMID: 7998989
9. Rh-related antigen CD47 is the signal-transducer integrin-associated protein.  |  Lindberg, FP., et al. 1994. J Biol Chem. 269: 1567-70. PMID: 8294396
10. Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells.  |  Ticchioni, M., et al. 1997. J Immunol. 158: 677-84. PMID: 8992983
11. Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate.  |  Nishiyama, Y., et al. 1997. Jpn J Cancer Res. 88: 120-8. PMID: 9119739

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD47 Antibody (B6H12) has 48 citations in a variety of scientific publications.

Primary antibodies like Anti-CD47 Antibody (B6H12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD47 Antibody (B6H12) Specifications

Alternate Product Name: CD47

Product Clone Name: B6H12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CD47

Epitope Species: human

Product Reactivity/Detection: the immunoglobulin domain of CD47

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 48 citations in various scientific publications

Available Conjugates/Forms for CD47 Antibody (B6H12): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, PE: Phycoerythrin